Clinical trial
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
NCT03420781 is registered in ClinicalTrials.gov with Allergan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
- Lead sponsor
- Allergan
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 24, 2018
- Completion date
- October 30, 2020
- Enrollment
- 467 (actual)
- Sites
- 337
Conditions
As the registry lists them; a condition with its own page is linked.